Cancellation of state registration. Tenliza

February 08, 2018
Active substances:
ICD-10:
IX.I10-I15.I10    Essential [primary] hypertension
IX.I20-I25.I20    Angina pectoris [angina pectoris]
IX.I20-I25.I20.0    Unstable angina
IX.I20-I25.I20.1    Angina with documented spasm
IX.I30-I52.I50.0    Congestive heart failure
Amlodipine, lisinopril, combined antihypertensive drug, essential hypertension, angina pectoris, angina pectoris treatment, heart failure, stenocardia Prinzmetal

The Ministry of Health of the Russian Federation, in accordance with Article 32 of Federal Law No. 61-FZ of 12.04.2010 "On circulation of medicines", decided to abolish state registration and exclude from the state register of medicinal products for the medical use of the medicinal product (registration certificate LP-002894 dated 03/04/2015, issued by KRKA-RUS LLC, Russia, registration certificate LP-002899 dated 03/05/2015, issued by KRKA-RUS LLC, Russia):

Tenliza (trade name of the medicinal product)

Amlodipine +Lisinopril (international non-proprietary or chemical name of the medicinal product)

tablets, 5 mg + 20 mg tablets, 10 mg + 10 mg (dosage form, dosage)

KRKA-RUS, LLC, Russia 143500, Moscow Region, Istra, ul. Moscow, 50 (name and address of the location of the manufacturer of the medicinal product)

on the basis of the filing by an authorized legal entity of the representative office of the company KRKA-RUS, Russia, a request for the cancellation of state registration medicinal preparation.